Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: relationship with tumor size and cell differentiation

Arisa Kumagai · Fukuo Kondo · Keiji Sano · Masafumi Inoue · Takeshi Fujii · Masaji Hashimoto · Masato Watanabe · Yurie Soejima · Tsuyoshi Ishida · Takuo Tokairin · Koji Saito · Yuko Sasajima · Yoshihisa Takahashi · Hiroshi Uozaki · Toshio Fukusato

Published online: 12 June 2016
© 2016 The Authors. Journal of Hepato-Biliary-Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato-Biliary-Pancreatic Surgery.

The author’s affiliations are listed in the Appendix.

Correspondence to: Fukuo Kondo, Department of Pathology, Teikyo University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan e-mail: fkondo55@med.teikyo-u.ac.jp

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1002/jhbp.356

Abstract

Background  The purpose of this study is to investigate whether ordinary hepatocellular carcinomas (HCCs) show positivity of stem/progenitor cell markers and cholangiocyte markers during the process of tumor progression.

Methods  Ninety-four HCC lesions no larger than 8 cm from 94 patients were immunohistochemically studied using two hepatocyte markers (Hep par 1 and α-fetoprotein), five cholangiocyte markers (cytokeratin CK7, CK19, Muc1, epithelial membrane antigen and carcinoembryonic antigen) and three hepatic stem/progenitor cell markers (CD56, c-Kit and EpCAM). The tumors were classified into three groups by tumor size: S1, < 2.0 cm; S2, 2.0–5.0 cm; S3, 5.0–8.0 cm. The tumors were also classified according to tumor differentiation: well, moderately and poorly differentiated. The relationship between the positive ratios of these markers, tumor size and tumor differentiation was examined.

Results  The positive ratios of cholangiocyte markers tended to be higher in larger sized and more poorly differentiated tumors (except for CK7). The positive ratios of stem/progenitor cell markers tended to be higher in larger sized and more poorly differentiated tumors (except for c-Kit).

Conclusion  Ordinary HCC can acquire the characteristic of positivity of cholangiocyte and stem/progenitor cell markers during the process of tumor progression.

Keywords  Hepatocellular carcinoma · Immunohistochemistry · Progenitor cell · Stem cell · Transdifferentiation

Introduction

Owing to the recent advance of studies of primary liver cancer with stem/progenitor cell features and/or biliary differentiation [1–8], classification of combined hepatocellular-cholangiocarcinoma (CH-CC) was newly created [9]. CH-CC is now classified into classical type and subtypes with stem cell features. At present, the formation mechanism of CH-CC can be classified into two types: (i) hepatocellular carcinoma transdifferentiating into CH-CC, and (ii) malignant transformation of stem/progenitor cells. Of these two, the classical type can be an example of the first pathway, and the subtypes with stem cell features can be examples of the second pathway. After this dramatic revision of the classification, several important works of CH-CC with stem cell features were published [10–12].

Studies of transdifferentiation have greatly progressed, as well as those of stem/progenitor cells [13–17]. In a former study [18], we examined the expression of cholangiocyte and stem
cell markers in ordinary hepatocellular carcinoma (HCC) tissues. The results suggested that this expression could be interpreted as transdifferentiation. However, the relationship between the positive ratio of these markers, tumor size and tumor differentiation was not examined. Various stem cell/progenitor cell markers were not examined, except for c-Kit.

In the present study, we examined the positive ratios of various markers of hepatocyte, cholangiocyte and stem/progenitor cells in ordinary HCC cases. The data were then compared with tumor size and tumor differentiation. We investigated whether ordinary HCCs show positivity of various markers during the process of tumor progression.

**Methods**

**Patients and tissue specimens**

Tissue samples from 94 patients with ordinary HCC were obtained by surgical resection at the Department of Surgery, Teikyo University Hospital and Toranomon Hospital in 2001–2009. Their clinico-pathological data are shown in Table 1. These HCC patients consisted of 73 men and 21 women ranging in age from 44 to 82 years (mean, 67 years). Thirteen patients were positive for serum hepatitis B surface antigen, 66 were positive for serum anti-hepatitis C virus antibody, and 15 were negative for both. The large diameters of these 94 tumors ranged from 0.9 to 8.0 cm (mean, 3.1 cm).

Histological diagnosis and classification of differentiation of these HCCs were made according to the World Health Organization (WHO) classification [19]. As for tumor cell differentiation, 16 cases were well-differentiated, 74 cases were moderately differentiated, and four cases were poorly differentiated. Histological type was predominantly the ordinary trabecular type in all 94 cases; pseudoglandular type was found as a minor component.

### Table 1 Clinico-pathological data

| Parameter            | Value                                      |
|----------------------|--------------------------------------------|
| Age                  | 44–82 years (mean, 67 years)               |
| Gender               | Male, 73 cases; female, 21 cases           |
| Causative factors of liver disease | HBsAg+, 13 cases; HCAb+, 66 cases          |
| Non-cancerous liver tissue | NL, 3 cases; CH, 46 cases; LC, 45 cases   |
| Tumor size           | 0.9–8.0 cm (mean, 3.1 cm)                  |
| Cell differentiation  | Well, 16 cases; moderate, 74 cases; poor, 4 cases |

*CH chronic hepatitis, HBsAg hepatitis B surface antigen, HCAb hepatitis C antibody, LC liver cirrhosis, NL normal liver*

Special types, such as scirrhou, fibrolamellar and sarcomatous were not found.

The diagnostic criteria of ordinary HCC and differentiation from CH-CC were based on the mucin staining. We defined ordinary HCC as those cases whose mucin-positive area is less than 10%. The lesion whose mucin-positive area was larger than 10% was classified as a CH-CC. In our previous study, 68 HCC cases were studied [18]. One case was deleted from these 68 cases because the mucin-positive area was larger than 10%. The rest of 67 cases were included in the present study.

The surrounding non-tumorous liver tissues showed chronic hepatitis in 46 patients and cirrhotic change in 45 patients. The other three patients showed normal liver.

This study was approved by the Research Ethics Review Board of the Teikyo University School of Medicine and Toranomon Hospital.

This study was approved in part by grants from The Vehicle Racing Commemorative Foundation.

**Immunohistochemistry**

Tissue samples were fixed in 10% formalin solution and embedded in paraffin for histological diagnosis and immunohistochemistry.

The primary antibodies are summarized in Table 2. Hep par 1 and α-fetoprotein (AFP) were used as hepatocyte markers. Cytokeratin 7 (CK7), cytokeratin 19 (CK19), Muc 1, carcinoembryonic antigen (CEA) and epithelial membrane antigen (EMA) were used as cholangiocyte markers. CD56, c-Kit, and EpCAM were used as stem cell/progenitor cell markers.

Formalin-fixed paraffin-embedded tissue samples, cut at 3-μm thickness, were deparaffinized with xylene and rehydrated with graded ethanol. Antigen retrieval was performed by boiling at 98°C for 40 minutes in 0.01 mol/L sodium citrate buffer (pH 6.0), or in Tris/EDTA buffer (pH9.0). Immunohistochemistry was performed using Dako Autostainer plus (Dako, Glostrup, Denmark). Endogenous peroxidase was quenched with 3% H2O2 in distilled water for 5 min. After treatment with protein blocking solution (Dako) for 10 min, the slides were incubated with primary antibodies for 30 min at room temperature. The sections were then stained by the detection method using EnVision kit (Dako ChemMate) according to the manufacturer’s protocol and counterstained with hematoxylin.

The expression of these markers was evaluated semiquantitatively as follows:

- Negative (Score 0); No positive staining, or tumor cells were not stained with a clustered pattern e.g. less than five definitively positive cells in a cluster.
1+ (Score 1); Tumor cells were stained with a clustered pattern e.g. at least five definitively positive cells in a cluster. Positive cells were less than 5% of the specimen.

2+ (Score 2); 5–10%, 3+ (Score 3); 10–50%, 4+ (Score 4); 50–100%.

Positive ratio was calculated by the following formula:

\[ \text{Positive ratio} = \left( \frac{\text{Number of positive lesions}}{\text{Number of all lesions}} \right) \times 100 \% \]

Because semiquantitative evaluation of membranous pattern (canalicular staining) of CEA and EMA was very difficult, we evaluated only cytoplasmic pattern in CEA and EMA.

Statistical analysis

The tumors were classified into three groups by tumor size (long axis) and cell differentiation. The groups of tumor size were classified as follows: S1, < 2.0 cm (29 cases); S2, 2.0–5.0 cm (54 cases); S3, 5.0–8.0 cm (11 cases). The groups of tumor cell differentiation were classified as follows according to WHO classification: well-differentiated (16 cases), moderately differentiated (74 cases), and poorly differentiated (four cases).

Data of simple positive ratio were analyzed using Fisher’s exact test to evaluate the significance of differences among the groups by tumor size and cell differentiation, respectively. Semiquantitative immunohistochemical score (0/1/2/3/4) of these groups were analyzed using Kruskal–Wallis analysis. \( P < 0.05 \) was considered statistically significant.

Results

The simple positive ratio and semiquantitative immunohistochemical score of the groups are summarized in Table 3 (correlation with tumor size) and Table 4 (correlation with cell differentiation).

Correlation between the immunohistochemical positive ratio of hepatocyte, cholangiocyte, stem/progenitor cell markers and tumor size

**Hepatocyte markers: Hep par 1 and AFP**

Hep par 1 showed cytoplasmic staining with coarsely granular patterns in HCC cells (Fig. 1a), which was more heterogeneous than that of hepatocytes both in normal and non-neoplastic liver tissues with chronic liver disease. All 94 HCC cases were positive for Hep par 1 regardless of tumor size (Table 3). Positive staining of AFP was found in none of 29 (0%) cases of S1, 7/54 (12.9%) cases of S2, and 2/11 (18.2%) cases of S3 (Table 3) (Fig. 1b). Although not statistically significant, the positive ratio of AFP was the lowest in the S1 HCC group, and the highest in the S3 HCC group.

**Cholangiocyte markers: CK7, CK19, Muc1, CEA and EMA**

CK7 was positively stained in 24/29 (82.8%) cases of S1, 38/54 (70.4%) cases of S2, and 9/11 (81.8%) cases of S3 (Table 3) (Fig. 1c). While the positive ratio of CK7 varied, more than 75% (71/94, 75.5%) cases in this study were positive for this cholangiocyte marker.

By contrast, the positive ratio of CK19 was lower than that of CK7 in each HCC group. The positive ratio was 4/29 (13.8%) cases of S1, 10/54 (18.5%) cases of S2, and 4/11 (36.4%) cases of S3 (Table 3) (Fig. 1d). Although it was not statistically significant, the group with larger HCCs tended to show a higher positive ratio than the group with smaller HCCs.

Muc1 was positively stained in 2/29 cases (6.9%) of S1, 5/54 (9.3%) cases of S2, and 5/11 (45.5%) cases of S3 (Table 3) (Fig. 1e). The positive ratio of Muc1 in the S3 HCC group was significantly higher than that of the S1 \( (P < 0.01) \) and S2 HCC groups \( (P < 0.05) \). Semiquantitative scores of these groups were significantly different \( (P < 0.01) \).
A cytoplasmic staining pattern of CEA was found in 11/94 (11.7%) examined HCCs (Fig. 1f), and its appearance was correlated with tumor size: none of 29 (0%) cases of S1, 6/54 (11.1%) cases of S2, and 5/11 (45.5%) cases of S3 (Table 3). The positive ratio of CEA expression in the S3 HCC group was significantly higher than those of the S1 (P < 0.001) and S2 HCC groups (P < 0.05). Semiquantitative analysis of the scores was also significant (P < 0.001).

A cytoplasmic staining pattern of EMA was found in 14/94 (14.9%) examined HCCs (Fig. 1g), and its appearance was observed in 2/29 (6.9%) cases of S1, 9/54 (16.7%) cases of S2, and 3/11 (27.3%) cases of S3 (Table 3). The positive ratio of EMA expression with cytoplasmic patterns in the group with large HCCs tended to be higher than that of the group with small HCCs, although the difference was not significant.

**Stem/progenitor cell markers: CD56, c-Kit and EpCAM**

CD56 was found in 9/94 (9.6%) HCCs, and they were correlated with tumor size; 1/29 (3.4%) cases of S1, 4/54 (7.4%) cases of S2, and 4/11 (36.4%) cases of S3 showed positive staining (Table 3) (Fig. 1h). The positive ratio of CD56 expression in the S3 HCC group was significantly higher than those of the S1 (P < 0.05) and S2 HCC groups (P < 0.05). Semiquantitative analysis was also proved to be significant (P < 0.01).

### Table 3  Semiquantitative evaluation of hepatocyte, cholangiocyte, and stem/progenitor cell markers; the correlation with tumor size

| Group of tumor size | Number of positive cases | Positive ratio (%) | P-value (S1 vs. S2/S1 vs. S3/S2 vs. S3) | Score of immunohistochemistry (0/1/2/3/4)a | P-value |
|---------------------|--------------------------|--------------------|------------------------------------------|-------------------------------------------|---------|
| Hep par 1           | S1 (n = 29)              | 29                 | 100%                                     | N/A                                       | 0.143   |
|                     | S2 (n = 54)              | 54                 | 100%                                     | 0/0/0/0/24                                |         |
|                     | S3 (n = 11)              | 11                 | 100%                                     | 0/0/0/0/11                                |         |
| AFP                 | S1 (n = 29)              | 0                  | 0%                                       | 0.090/0.071/0.642                         | 0.098   |
|                     | S2 (n = 54)              | 7                  | 12.9%                                    | 47/1/11/3/2                               |         |
|                     | S3 (n = 11)              | 2                  | 18.2%                                    | 9/1/0/0/1                                 |         |
| CK7                 | S1 (n = 29)              | 24                 | 82.8%                                    | 0.292/1.000/0.713                         | 0.539   |
|                     | S2 (n = 54)              | 38                 | 70.4%                                    | 16/9/12/13/4                              |         |
|                     | S3 (n = 11)              | 9                  | 81.8%                                    | 20/5/3/1                                 |         |
| CK19                | S1 (n = 29)              | 4                  | 13.8%                                    | 0.761/0.182/0.232                         | 0.253   |
|                     | S2 (n = 54)              | 10                 | 18.5%                                    | 44/7/3/0/0                                |         |
|                     | S3 (n = 11)              | 4                  | 36.4%                                    | 7/2/0/0                                  |         |
| Muc1                | S1 (n = 29)              | 2                  | 6.9%                                     | 1.000/0.011/0.009                         | < 0.001 |
|                     | S2 (n = 54)              | 5                  | 9.3%                                     | 49/3/2/0                                  | 0.193   |
|                     | S3 (n = 11)              | 5                  | 45.5%                                    | 6/2/3/0                                  |         |
| CEA                 | S1 (n = 29)              | 0                  | 0%                                       | 0.087/0.001/0.015                         | < 0.001 |
|                     | S2 (n = 54)              | 6                  | 11.1%                                    | 48/4/1/1/0                                |         |
|                     | S3 (n = 11)              | 5                  | 45.5%                                    | 6/3/2/0                                  |         |
| EMA                 | S1 (n = 29)              | 2                  | 6.9%                                     | 0.316/0.125/0.412                         | 0.193   |
|                     | S2 (n = 54)              | 9                  | 16.7%                                    | 45/5/3/1                                  |         |
|                     | S3 (n = 11)              | 3                  | 27.3%                                    | 8/1/1/1                                  |         |
| CD56                | S1 (n = 29)              | 1                  | 3.4%                                     | 0.653/0.015/0.023                         | 0.004   |
|                     | S2 (n = 54)              | 4                  | 7.4%                                     | 50/3/0/1/0                                |         |
|                     | S3 (n = 11)              | 4                  | 36.4%                                    | 7/2/0/2/0                                |         |
| c-kit               | S1 (n = 29)              | 0                  | 0%                                       | N/A                                       | N/A     |
|                     | S2 (n = 54)              | 0                  | 0%                                       | 54/0/0/0                                  |         |
|                     | S3 (n = 11)              | 0                  | 0%                                       | 11/0/0/0                                  |         |
| EpCAM               | S1 (n = 29)              | 1                  | 3.4%                                     | 0.412/0.479/1.000                         | 0.512   |
|                     | S2 (n = 54)              | 6                  | 11.1%                                    | 48/4/1/1/0                                |         |
|                     | S3 (n = 11)              | 1                  | 9.1%                                     | 10/0/0/0/1                               |         |

*AFP α-fetoprotein, CK7 cytokeratin 7, CK19 cytokeratin 19, CEA carcinoembryonic antigen, EMA epithelial membrane antigen, N/A not available

a Score 0, negative; score 1, a clustered pattern (at least five definitively positive cells in a cluster) < 5% positive cells; score 2, 6% to 10% positive cells; score 3, 10% to 50% positive cells; score 4, 50% to 100% positive cells
b P < 0.05
c P < 0.01
The expression of c-Kit was not found in any of the examined 94 HCC cases (Table 3). Although our former paper reported that eight cases of HCC showed positive staining [18], the number of positive cells was very few. These findings were not sufficient for the criteria of positivity in the present study.

The positive ratios of EpCAM of the S1, S2 and S3 groups were 1/29 (3.4%), 6/54 (11.1%), and 1/11 (9.1%), respectively (Table 3) (Fig. 1i). The positive ratio of EpCAM did not show the highest value in the largest S3 HCC group. However, the positive ratio of the smallest S1 group showed the smallest value. In addition, a case of S3 group showed the highest score 4 in the semiquantitative evaluation.

### Table 4 Semiquantitative evaluation of hepatocyte, cholangiocyte, and stem/progenitor cell markers; the correlation with cell differentiation

| Cell differentiation | Number of positive cases | Positive ratio (%) | P-value (well vs. moderately/ well vs. poorly/ moderately vs. poorly) | Score of immunohistochemistry (0/1/2/3/4)* | P-value |
|----------------------|--------------------------|--------------------|--------------------------------------------------------------------|-------------------------------------------|---------|
| Hep par 1            |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 16                       | 100                | N/A                                                                | 0/0/4/0/12                                | 0.024*  |
| Moderately (n = 74)  | 74                       | 100                |                                                                    | 0/0/1/3/70                                |         |
| Poorly (n = 4)       | 4                        | 100                |                                                                    | 0/0/0/1/3                                |         |
| AFP                  |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 0                        | 0                  | 0.342/0.200/0.394                                                  | 16/0/0/0                                 | 0.236   |
| Moderately (n = 74)  | 8                        | 10.8               |                                                                    | 66/2/1/2/3                               |         |
| Poorly (n = 4)       | 1                        | 25.0               |                                                                    | 3/0/0/1/0                                |         |
| CK7                  |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 14                       | 87.5               | 0.508/0.032^2/0.057                                                | 2/6/5/3/0                                | 0.272   |
| Moderately (n = 74)  | 56                       | 75.7               |                                                                    | 18/10/22/18/6                            |         |
| Poorly (n = 4)       | 1                        | 25.0               |                                                                    | 3/0/0/1/0                                |         |
| CK19                 |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 3                        | 18.8               | 1.000/0.249/0.165                                                  | 13/2/1/0/0                               | 0.378   |
| Moderately (n = 74)  | 13                       | 17.6               |                                                                    | 61/7/6/0/0                               |         |
| Poorly (n = 4)       | 2                        | 50.0               |                                                                    | 2/2/0/0/0                                |         |
| Muc1                 |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 0                        | 0                  | 0.353/0.004^2/0.011                                                | 16/0/0/0                                 | < 0.001 |
| Moderately (n = 74)  | 9                        | 12.2               |                                                                    | 65/5/4/0/0                               |         |
| Poorly (n = 4)       | 3                        | 75.0               |                                                                    | 1/2/1/0/0                                |         |
| CEA                  |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 0                        | 0                  | 0.202/ N/A /1.000                                                  | 16/0/0/0                                 | 0.190   |
| Moderately (n = 74)  | 11                       | 14.9               |                                                                    | 63/7/3/1/00                              |         |
| Poorly (n = 4)       | 0                        | 0                  |                                                                    | 4/0/0/0/0                                |         |
| EMA                  |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 0                        | 0                  | 0.206/0.035^2/0.146                                                | 16/0/0/0                                 | 0.036^b |
| Moderately (n = 74)  | 12                       | 16.2               |                                                                    | 62/7/3/2/00                              |         |
| Poorly (n = 4)       | 2                        | 50.0               |                                                                    | 2/1/1/0/0                                |         |
| CD56                 |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 1                        | 6.2                | 1.000/0.088/0.050                                                  | 15/1/0/0/0                               | 0.017^b |
| Moderately (n = 74)  | 6                        | 8.1                |                                                                    | 68/4/0/2/0                               |         |
| Poorly (n = 4)       | 2                        | 50.0               |                                                                    | 2/1/0/1/0                                |         |
| c-kit                |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 0                        | 0                  | N/A                                                                | 16/0/0/0                                 | N/A     |
| Moderately (n = 74)  | 0                        | 0                  |                                                                    | 74/0/0/0/0                               |         |
| Poorly (n = 4)       | 0                        | 0                  |                                                                    | 4/0/0/0/0                                |         |
| EpCAM                |                          |                    |                                                                    |                                           |         |
| Well (n = 16)        | 0                        | 0                  | 0.342/ N/A/1.000                                                   | 16/0/0/0                                 | 0.311   |
| Moderately (n = 74)  | 8                        | 10.8               |                                                                    | 66/4/2/3/1                               |         |
| Poorly (n = 4)       | 0                        | 0                  |                                                                    | 4/0/0/0/0                                |         |

*AFP α-fetoprotein, CK7 cytokeratin 7, CK19 cytokeratin 19, CEA carcinoembryonic antigen, EMA epithelial membrane antigen, N/A not available

a Score 0, negative; score 1, a clustered pattern (at least five definitively positive cells in a cluster) < 5% positive cells; score 2, 6% to 10% positive cells; score 3, 10% to 50% positive cells; score 4, 50% to 100% positive cells

b P < 0.05

c P < 0.01

The expression of c-Kit was not found in any of the examined 94 HCC cases (Table 3). Although our former paper reported that eight cases of HCC showed positive staining [18], the number of positive cells was very few. These findings were not sufficient for the criteria of positivity in the present study.

The positive ratios of EpCAM of the S1, S2 and S3 groups were 1/29 (3.4%), 6/54 (11.1%), and 1/11 (9.1%), respectively (Table 3) (Fig. 1i). The positive ratio of EpCAM did not show the highest value in the largest S3 HCC group. However, the positive ratio of the smallest S1 group showed the smallest value. In addition, a case of S3 group showed the highest score 4 in the semiquantitative evaluation.

Correlation between the immunohistochemical positive ratio of hepatocyte, cholangiocyte, stem/progenitor cell markers and tumor cell differentiation

**Hepatocyte markers: Hep par 1 and AFP**

All of 94 HCC cases were positive for Hep par 1 regardless of cell differentiation (Table 4). AFP was positively stained in none of 16 (0%) cases of the well-differentiated HCC group, 8/74 (10.8%) cases of the moderately differentiated HCC group, and 1/4 (25%) cases of the poorly differentiated HCC group (Table 4). The positive ratios...
of AFP-expressing HCCs were higher in the poorer differentiated HCCs, although this was not statistically significant.

**Cholangiocyte markers: CK7, CK19, Muc1, CEA and EMA**

CK7 was positively stained in 14/16 cases (87.5%) of the well-differentiated, 56/74 (75.7%) cases of the moderately differentiated, and 1/4 (25%) cases of the poorly differentiated HCC groups (Table 4). The positive ratio of CK7 expression in the poorly differentiated HCC group was significantly lower than those of the well-differentiated ($P < 0.05$). However, semiquantitative analysis of the scores was not significant.

CK19 was positively stained in 3/16 (18.8%) cases of the well-differentiated, 13/74 (17.6%) cases of the moderately differentiated, and 2/4 (50%) cases of the poorly differentiated HCC groups (Table 4). The positive ratio of CK19 in the poorly differentiated HCC group was higher than those of the well-differentiated and moderately differentiated HCC groups, although not to a statistically significant degree.

Muc1 was positively stained in none of 16 cases (0%) of the well-differentiated, 9/74 (12.2%) cases of the moderately differentiated, and 3/4 (75%) cases of the poorly differentiated HCC groups (Table 4). The positive ratio of Muc1 of the poorly differentiated HCC group was significantly higher than those of the well-differentiated ($P < 0.01$) and moderately differentiated HCC groups ($P < 0.05$). Semiquantitative analysis...
was also proved to be significant with a very low P-value ($P < 0.001$).

A cytoplasmic staining pattern of CEA was found in 11/74 (14.9%) cases of the moderately differentiated HCC group but not in the well-differentiated and poorly differentiated HCC groups (Table 4).

A cytoplasmic staining pattern of EMA was found in none of 16 (0%) cases of the well-differentiated, 12/74 (16.2%) cases of the moderately differentiated, and 2/4 (50%) cases of the poorly differentiated HCC groups. The positive ratio of EMA with cytoplasmic patterns in the poorly differentiated HCC group was significantly higher than that of the well-differentiated HCC group ($P < 0.05$). Semiquantitative analysis was also significant ($P < 0.05$).

**Stem/progenitor cell markers: CD56, c-Kit and EpCAM**

CD56 was positively stained in 1/16 cases (6.2%) of the well-differentiated, 6/74 (8.1%) cases of the moderately differentiated, and 2/4 (50%) cases of the poorly differentiated HCC groups (Table 4). The positive ratio of CD56 in the poorly differentiated HCC group was higher than those of the moderately and well-differentiated HCC groups, although the difference was not statistically significant. The expression of c-Kit was not found in any of the 94 HCC cases (Table 4).

The positive ratios of EpCAM of the well-, moderately-, and poorly-differentiated group were 0/16 (0%), 8/74 (10.8%), and 0/4 (0%), respectively (Table 4).

**Discussion**

The WHO classification of CH-CC has been entirely revised [9] on the basis of recent advances in stem/progenitor cell studies [1–5]. It is speculated that some of these CH-CC are of stem/progenitor cell origin [11]. They are now classified as subtypes with stem cell features. Evaluation of stem cell features and biliary differentiation is truly important because these stem/progenitor cell and/or biliary characteristic of the primary liver cancer is closely related to their clinical behavior [6–8, 10, 12]. However, it is still controversial whether they actually originated from stem/progenitor cells. Their stem/progenitor cell features could be acquired phenotypes during the process of transdifferentiation. Studies of transdifferentiation have also progressed considerably [13–17]. According to those studies, cholangiocellular carcinoma phenotype can be derived from HCC component [13–15]. In animal models, non-neoplastic hepatocytes are able to transdifferentiate into cholangiocytes [16, 17].

Those studies provide evidence of CH-CC of the classical type, which is considered to be formed by transdifferentiation. Our previous study also showed that ordinary HCC includes cholangiocyte marker-positive areas [18]. At present, however, we have little data as to the expression of stem/progenitor cell phenotypes caused by transdifferentiation. Our previous study did not deal with various stem cell/progenitor cell markers except for c-Kit.

In the present study, we added CD56 and EpCAM as stem/progenitor cell markers as well as c-Kit, as these markers were described as representative stem/progenitor cell markers by the WHO classification [9]. We added small and large HCCs to the former materials. And then, we examined the positive ratios of various markers of hepatocyte, cholangiocyte and stem/progenitor cells in ordinary HCC cases. In addition, we evaluated immunostaining semiquantitatively. The data were compared with tumor size and tumor cell differentiation.

The positive ratio of cholangiocyte markers CK19, Muc1, CEA and EMA tended to be higher in larger sized and more poorly differentiated tumors. These results support the formation mechanism of the classical type of CH-CC, which is formed by transdifferentiation. According to animal model studies, non-neoplastic hepatocytes can also transform into cholangiocytes [16, 17].

The positive ratio of the stem/progenitor cell markers also showed a similar tendency. CD56 tended to show a higher positive ratio in larger sized and more poorly differentiated tumors. EpCAM was positive only in the moderately differentiated HCC group. None of the well-differentiated HCCs was positively stained. These results suggest the possibility that expressions of stem/progenitor cell markers are acquired phenotypes during the process of tumor progression. The expression of stem cell features itself does not necessarily mean a stem/progenitor cell origin. Transdifferentiation can be another type of the formation mechanism of subtypes of stem cell features.

The significance of stem/progenitor cell markers should also be considered. In fact, CD56 and EpCAM are sometimes positively stained in non-neoplastic bile ducts. Interlobular bile ducts also show positivity of c-Kit [20]. These stem/progenitor cell markers can be interpreted as bile duct markers. Therefore, CH-CC with stem cell features might have been formed by bile duct transformation.

The distribution pattern of new phenotype foci within the tumor nodule should be carefully examined when speculating about the tumor cell origin [18]. If CH-CC foci emerged within a pre-existing stem/progenitor cell tumor nodule, stem cell marker-negative foci must exist as small areas within a large positive nodule. If stem/progenitor cell marker-positive foci emerged within a pre-existing ordinary HCC, stem cell marker-positive foci must exist as small areas within a large negative nodule. In evaluating the new phenotypic foci, the cutoff value of the immunostaining must be settled at a very low level. By this reasoning, in the present study a small clustered positive area was evaluated as a positive area. In this study, all the stem/progenitor cell marker-positive foci were found as “small positive foci in a large negative area” [18].
The cholangiocyte markers were also found with the same pattern. These distribution patterns suggested that the stem/progenitor cell markers as well as the cholangiocyte markers emerged as a result of transdifferentiation. These results must be attributed to the methods of this study, in which various phenotypes were examined within ordinary HCC tissues.

In the future, we will need to search for other types of the tumors that show small stem/progenitor cell marker-negative areas within a large positive area. If we find such types of tumors, they must be recognized as being from stem/progenitor cell origin.

As far as the present HCC cases are concerned, stem/progenitor cell features appeared as acquired phenotypes during the process of tumor progression. We should think of the possibility of transdifferentiation when we find stem cell features within HCC tissues besides the possibility of stem cell origin. Of course, tumors of stem/progenitor cell origin should also be pursued.

Conflict of interest None declared.

Appendix: author’s affiliations

Arisa Kumagai, Masato Watanabe, Yoshihisa Takahashi, Hiroshi Uozaki and Tosho Fukusato, Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan; Fukuo Kondo, Tsuyoshi Ishida, Takuo Tokairin, Koji Saito and Yuko Sasajima, Department of Pathology, Teikyo University Hospital, Tokyo, Japan; Keiji Sano, Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan; Masafumi Inoue, Department of Diagnostic Pathology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan; Takeshi Fujii, Department of Pathology, Toranomon Hospital, Tokyo, Japan; Masaji Hashimoto, Department of Digestive Surgery, Hepatopancreatobiliary Surgery Unit, Toranomon Hospital, Tokyo, Japan; Yurie Soejima, Department of Molecular Pathology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

References

1. Robrechts C, De Vos R, Van den Heuvel M, Van Cutsem E, VanDamme B, Desmet V, et al. Primary liver tumour of intermediate (hepatocyte–bile duct cell) phenotype: a progenitor cell tumour? Liver. 1998;18:288–93.
2. Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, et al. Hepatic “stem cell” malignancies in adults: four cases. Histopathology. 2003;43:263–71.
3. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, et al. Primary liver carcinoma of intermediate (hepatocyte–cholangiocyte) phenotype. J Hepatol. 2004;40:298–304.
4. Durnez A, Verslype C, Nevens F, Feverly J, Aerts R, Prienje J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138–51.
5. Taguchi J, Nakashima O, Tanaka M, Hsaka T, Takazawa T, Kojiori M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996;11:758–64.
6. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomoi A, et al. Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol. 2006;37:283–91.
7. Aishima S, Nishihara Y, Kuroda Y, Taguchi K, Iguchi T, Taketomi A, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol. 2007;31:783–91.
8. Yamashita T, Ji J, Badhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012–24.
9. Theise ND, Nakashima O, Park YN, Nakamura Y. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND editors. WHO classification of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 198–204.
10. Ikeda H, Harada K, Sato Y, Sasaki M, Yoneda N, Kitamura S, et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol. 2013;140:329–40.
11. Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013;37:496–505.
12. Sasaki M, Sato H, Kakada Y, Sato Y, Chiy HJ, Nakamura Y. Clinicopathological significance of ‘subtypes with stem-cell feature’ in combined hepatocellular-cholangiocarcinoma. Liver Int. 2015;35:1024–35.
13. Yano H, Kojiro M, Nakashima T. A new human hepatocellular carcinoma cell line (KYN-1) with a transformation to adenocarcinoma. In Vitro Cell Dev Biol. 1986;22:637–46.
14. Yoneda N, Sato Y, Kitao A, Ikeda H, Sawada-Kitamura S, Miyakoshi M, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest. 2011;91:262–72.
15. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012;122:3914–8.
16. Nishikawa Y, Doi Y, Watanabe H, Tokairin T, Omori Y, Su M, et al. Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol. 2005;166:1077–88.
17. Nishikawa Y, Sone M, Nagahama Y, Kumagai E, Doi Y, Omori Y, et al. Tumor necrosis factor-α promotes bile ductular transdifferentiation of mature rat hepatocytes in vitro. J Cell Biochem. 2013;114:831–43.
18. Shibuya M, Kondo F, Sano K, Takada T, Asano T. Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2011;18:537–43.
19. Theise ND, Curado MP, Franchesci S, Hytiroglou P, Kudo M. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND editors. WHO classification of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 205–16.
20. Maeno S, Kondo F, Sano K, Takada T, Asano T. Morphometric and immunohistochemical study of cholangiocellular carcinoma: comparison with non-neoplastic cholangiote, interlobular duct and septal duct. J Hepatobiliary Pancreat Sci. 2012;19:289–96.